News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Drug Data Delay Offers Actelion Ltd. Bid Shield
February 16, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, Feb 16 (Reuters) - Actelion (ATLN.VX), Europe's biggest biotech group, could be immune from takeover until the end of the year when data on a key heart and lung drug is due.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Europe
MORE ON THIS TOPIC
Legal
Delaware Court Denies Pfizer’s Bid To Block Novo-Metsera Deal
November 6, 2025
·
2 min read
·
Tristan Manalac
Obesity
Novo’s Metsera Bid Attracts FTC Scrutiny as Pfizer Matches $10B Offer
November 6, 2025
·
3 min read
·
Tristan Manalac
Business
Basel Life Sciences Scene Embraces International Companies, Startups
November 6, 2025
·
6 min read
·
Angela Gabriel
Obesity
Is Metsera Worth the Fuss?
November 5, 2025
·
4 min read
·
Annalee Armstrong
